France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts

Mar.10
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.

Key Points

 

HAS confirmation: France’s national health authority (Haute Autorité de Santé, HAS) confirmed to 2Firsts that updated smoking-cessation guidelines will address the role of e-cigarettes.

 

Timeline: The revised national cessation recommendations are currently under preparation and are expected to be published by the end of 2026.

 

Scope of guidance: HAS said the recommendations will focus on clinical and public-health considerations rather than establishing technical standards for vaping products.

 

Evidence limits: The agency noted that existing scientific studies remain insufficient to clearly assess the risks and benefits across different categories of vaping products.

 

Policy context: HAS said it is monitoring European regulatory developments and will consider them if they affect the guideline update.

 


 

2Firsts

March 10, 2026

 

France’s national health authority will address the role of e-cigarettes in updated smoking-cessation guidelines expected by the end of 2026, the agency told 2Firsts in response to questions about the ongoing revision of its national recommendations.

 

The Haute Autorité de Santé (HAS) said the updated recommendations on smoking cessation are currently under preparation and are scheduled for publication at the end of 2026. In its response to questions from 2Firsts, the agency said the working group responsible for the revision will examine “the place of e-cigarettes in the smoking-cessation process.”

 

The forthcoming document will update France’s 2014 national recommendations on tobacco cessation, which guide healthcare professionals in primary care on screening, treatment pathways and the maintenance of abstinence among smokers.

 

Guideline Update Underway

 

According to HAS, the revision of the cessation guidelines remains ongoing and the authority is not yet in a position to present final conclusions. The publication of the updated recommendations is planned for the end of 2026.

 

When asked whether vaping remains part of the scope of the guideline review, the agency confirmed that the topic continues to be included in the work currently being carried out.

 

“We will address the place of electronic cigarettes in the smoking-cessation process,” the HAS press office said in its written response to 2Firsts.

 

The agency did not indicate what conclusions the final recommendations might reach regarding the use of vaping products in cessation pathways.

 

No Technical Standards Planned

 

HAS also said the guideline update will not establish technical or product-level standards for vaping devices or e-liquids.

 

Responding to questions about potential methodological criteria for evaluating vaping products — such as emissions measurements, exposure levels or device quality standards — the agency said these issues fall outside the scope of the recommendations currently under preparation.

 

“This question is not included in the framing document and this type of work does not fall within the remit of the professional department responsible for the guidelines,” the agency said.

 

The recommendations therefore focus on clinical and public-health considerations rather than technical product regulation, according to HAS.

 

Evidence Gaps on Product Categories

 

HAS said differentiating between categories of vaping products remains difficult given the current scientific evidence base.

 

The agency said that while such differentiation could be desirable, it is challenging in practice because vaping technologies are evolving rapidly and existing research remains limited.

 

“Vaping products are constantly evolving and studies by category of vaping products are insufficient in number to precisely describe the benefits and risks of each type of product,” HAS said.

 

As a result, the working group responsible for the guideline revision may recommend further research in this area.

 

Monitoring EU Regulatory Developments

 

The agency also confirmed that it is monitoring regulatory developments at the European level related to tobacco and vaping products.

 

HAS said that if changes in European regulation affect its work, they will be taken into account in the guideline update.

 

European institutions are currently reviewing several elements of nicotine product regulation, including potential revisions to the Tobacco Products Directive and other related regulatory frameworks.

 

Scientific Context

 

France’s national health and safety agency, the Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES), published a scientific assessment in February 2026 concluding that vaping is less harmful than combustible tobacco but not risk-free.

 

The report reviewed available epidemiological and toxicological evidence and concluded that the absence of combustion significantly reduces exposure to many toxic substances compared with cigarette smoke, while emphasizing that scientific uncertainties remain regarding long-term health effects.

 

ANSES provides scientific risk assessments to inform public policy, while HAS is responsible for issuing clinical and public-health recommendations, including guidance related to smoking cessation.

 

Outlook

 

France’s updated cessation recommendations are expected to address how vaping products may be considered within the country’s clinical approach to tobacco dependence, though the authority has not indicated what conclusions the final document will reach.

 

For continued coverage of European regulatory developments related to vaping and nicotine products, follow reporting from 2Firsts.

 

Cover image generated by AI.


Further reading:

 

2FIRSTS | France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
2FIRSTS | France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s top health agency has confirmed that vaping is less harmful than smoking — but not risk-free — reshaping the country’s regulatory trajectory. As Paris withdraws a proposed vape tax and debates stricter ingredient, emissions and youth-protection rules, the ANSES report signals not prohibition, but tighter technical oversight. For manufacturers, retailers and EU policymakers, France may be previewing Europe’s next phase of nicotine governance.
www.2firsts.com

Italy Formally Submits Detailed Opinion to EU Obstructing Ireland's Disposable Vape Ban
Italy Formally Submits Detailed Opinion to EU Obstructing Ireland's Disposable Vape Ban
Italy's Ministry of Enterprises and Made in Italy has submitted a detailed opinion against Ireland's proposed "Public Health (Single Use Vapes) Bill 2025." Italy argued that the comprehensive ban on disposable vapes lacks scientific evidence, violates the EU principle of the free movement of goods, and conflicts with the existing Tobacco Products Directive.
Apr.10 by 2FIRSTS.ai
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
Special Report | China’s Two Sessions Revisit Consumption Tax Reform, Tobacco Tax Outlook Draws Attention
Special Report | China’s Two Sessions Revisit Consumption Tax Reform, Tobacco Tax Outlook Draws Attention
China’s 2026 “Two Sessions” again raised the issue of consumption tax reform. As the largest source of consumption tax revenue, the tobacco tax system—its collection stages, tax structure and regional revenue distribution—has re-entered the policy discussion. This article outlines the structure of China’s tobacco consumption tax, past adjustments and key areas of debate, providing international readers with background on one of the country’s most important tax categories.
Special Report
Mar.08
Brazil’s Teen E-Cigarette Experimentation Rate Rises to 29.6% Over Five Years
Brazil’s Teen E-Cigarette Experimentation Rate Rises to 29.6% Over Five Years
Brazil’s National School Health Survey (PeNSE) 2024 found that e-cigarette experimentation among students aged 13 to 17 rose from 16.8% in 2019 to 29.6% in 2024, while use in the previous 30 days increased from 8.6% to 26.3%. Over the same period, conventional cigarette experimentation fell from 22.6% to 18.5%, and hookah use declined from 26.9% to 16.4%.
Mar.26 by 2FIRSTS.ai
West Virginia Bill Would Direct USD 2.9 Million of Juul Settlement to Youth Tobacco and Vaping Prevention
West Virginia Bill Would Direct USD 2.9 Million of Juul Settlement to Youth Tobacco and Vaping Prevention
A bill completed during West Virginia’s 2026 regular legislative session would make a one-time allocation of USD 2.9 million from the state’s USD 7.9 million settlement with Juul to youth tobacco prevention and cessation programs.
Mar.19 by 2FIRSTS.ai
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.
Mar.03 by 2FIRSTS.ai